PHOENIX, Dec. 3, 2021 /PRNewswire/ -- Creative
Medical Technology Holdings, Inc. (the "Company") (NASDAQ: CELZ), a
commercial stage biotechnology company focused on a regenerative
approach to Immunotherapy, Urology, Neurology and Orthopedics,
today announced the pricing of the underwritten public offering of
3,875,000 shares of common stock and accompanying warrants to
purchase up to 3,875,000 shares of common stock at a combined
public offering price of $4.13.
The warrants have a per share exercise price of $4.13, are exercisable immediately, and expire
five years from the date of issuance. The aggregate gross
proceeds from the offering are expected to total approximately
$16 million, before deducting the
underwriting discounts and commissions and estimated offering
expenses payable by the Company and without giving effect to
proceeds from any subsequent exercise of warrants.
As a result of the offering, the Company's common stock will
become listed on the Nasdaq Capital Market and will trade under the
ticker symbol "CELZ" beginning December
3, 2021. The offering is expected to close on or about
December 7, 2021, subject to
customary closing conditions. In addition, the Company has granted
to the underwriters of the offering a 45-day option to purchase up
to 581,250 additional shares and/or additional warrants to purchase
up to 581,250 shares of common stock to cover over-allotments, if
any.
Roth Capital Partners is acting as sole manager for the
offering.
The securities described above are being sold by the Company
pursuant to a registration statement on Form S-1 (Registration No.
333-259834) that was previously filed by the Company with the
Securities and Exchange Commission (the "SEC") and declared
effective on December 2, 2021.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
The offering is being made only by means of the written
prospectus forming part of the effective registration
statement. Electronic copies of the accompanying prospectus
may be obtained, when available, by contacting Roth Capital
Partners, 888 San Clemente, Newport
Beach, CA 92660, Attn: Prospectus Department, telephone:
800-678-9147, or email at rothecm@roth.com, or by visiting the
SEC's website at http://www.sec.gov.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. is a commercial stage
biotechnology company focused on immunology, urology, neurology and
orthopedics using adult stem cell treatments and interrelated
regenerative technologies for the treatment of multiple
indications. For further information about the company go to
www.creativemedicaltechnology.com.
Forward-Looking Statements
This press release contains "forward-looking statements" about
the company's current expectations about future results,
performance, prospects and opportunities. Statements that are not
historical facts, such as "anticipates," "believes" and "expects"
or similar expressions, are forward-looking statements. These
statements are subject to a number of risks, uncertainties and
other factors that could cause actual results in future periods to
differ materially from what is expressed in, or implied by, these
statements. The factors which may influence the company's future
performance include the company's ability to obtain additional
capital to expand operations as planned, success in attracting
additional customers, obtaining necessary regulatory approvals,
enrollment of adequate numbers of patients in clinical trials, and
unforeseen difficulties in showing efficacy of the company's
products. These and other risk factors are described from time to
time in the company's filings with the Securities and Exchange
Commission, including, but not limited to, the Company's recent
registration statement on Form S-1 and reports on Forms 10-K and
10-Q. Unless required by law, the company assumes no obligation to
update or revise any forward-looking statements as a result of new
information or future events.
www.creativemedicaltechnology.com
www.CaverStem.com
www.FemCelz.com
www.StemSpine.com
www.immcelz.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-inc-prices-16-million-public-offering-and-uplisting-to-the-nasdaq-capital-market-301436907.html
SOURCE Creative Medical Technology Holdings, Inc.